Key Highlights

  • PolyPid fell 27% despite a $300 million Azurity commercialization deal for D-PLEX100.
  • Lisata Therapeutics fell 36% to a six-month low after Kuva Labs breached its tender offer agreement.
  • Celldex Therapeutics fell 7% after barzolvolimab missed its primary endpoint in prurigo nodularis.
  • Palvella Therapeutics rose 16% as LifeSci Capital reaffirmed its Buy rating despite an FDA Breakthrough Therapy denial.

A cluster of biopharma names moved sharply on a single day of corporate, clinical, and regulatory news, with eight companies posting double-digit or high-single-digit share price swings tied to distinct, company-specific catalysts spanning commercial deals, trial results, mergers, and shareholder votes.

Decliners

PolyPid (NASDAQ: PYPD) shares fell 27% to close at $3.74 despite establishing a sole commercial partnership with Azurity Pharmaceuticals to market and distribute D-PLEX100 in the U.S. and Canada for the prevention of abdominal surgical site infections. The deal includes a $15 million initial payment, another $15 million upon FDA acceptance of its NDA expected by August 1, 2026, and up to roughly $300 million in total milestone compensation plus tiered royalties. A domestic launch is anticipated in the first quarter of 2027 following a 60% risk reduction in the Phase 3 SHIELD II trial.

Lisata Therapeutics (NASDAQ: LSTA) fell 36% to $2.24, its lowest level in almost half a year, after Kuva Labs breached its contract by failing to finalize a tender offer acquisition. Approximately 6.1 million shares, representing 66.8% of the company, were tendered by the July 20 deadline, meeting the minimum acceptance threshold, but Kuva never delivered payment due to financing difficulties. Lisata is now exploring legal recourse against Kuva.

Celldex Therapeutics (NASDAQ: CLDX) shares were down 7% at $33.05 in extended hours after its Phase 2 trial of subcutaneous barzolvolimab in prurigo nodularis missed both its primary endpoint on the Worst Itch Numeric Rating Scale and key secondary skin-lesion endpoints. The drug did demonstrate systemic mast cell depletion, but the company is halting the program to focus on late-stage assets, including a Phase 3 chronic spontaneous urticaria readout expected in October 2026.

Calidi Biotherapeutics (NYSE: CLDI) fell 14% to $0.10 after disclosing a 1-for-16 reverse stock split set to take effect July 31, 2026, with all outstanding warrants, options, and convertible instruments to be proportionally adjusted.

Agios Pharmaceuticals (NASDAQ: AGIO) fell 7% to $37.36 after Phase 2 data for tebapivat in sickle cell disease showed hemoglobin responses of 29.4% to 47.1% versus 33.3% for placebo, a lack of differentiation that led the company to halt the program.

Advancers

Niki BioSolutions (NASDAQ: NIKI), formerly Aptorum Group Limited, rose 8% to $9.54 after finalizing its all-stock business combination with DiamiR Biosciences Corp., a transaction that included a 1-for-10 share consolidation and redomestication from the Cayman Islands to Delaware.

Palvella Therapeutics (NASDAQ: PVLA) rose 16% to $143.94 after LifeSci Capital reaffirmed its Buy rating and $225 price target, even as the FDA denied Breakthrough Therapy Designation for QTORIN in cutaneous vascular malformations. Analyst Sam Slutsky called the setback a procedural delay rather than a clinical failure, noting Phase 3 CVM trials remain on track for late 2026 and a rolling NDA for microcystic lymphatic malformations targets a possible 2027 approval; TD Cowen's $267 target and Fast Track status add to the bullish case.

Vyne Therapeutics (NASDAQ: VYNE) rose 11% to $0.89 after shareholders approved key proposals tied to its merger with Yarrow, including issuing shares to Yarrow equity holders, a share consolidation with a ratio to be set between 1-for-10 and 1-for-70, and an increase in authorized common stock to 300 million shares.

Market Reaction

The day's moves illustrate how differently the market can treat similarly sized corporate news within biopharma: PolyPid's roughly $300 million Azurity partnership and Palvella's FDA setback both drew double-digit stock reactions, but in opposite directions, underscoring that investors were weighing deal and trial specifics rather than reacting to headline size alone. Meanwhile, Lisata's decline reflects the collapse of an announced acquisition rather than an operating or clinical setback, a distinct risk category from the trial failures at Celldex and Agios.

Outlook

Several of these names now carry specific near-term catalysts: Celldex's Phase 3 CSU readout is due in October 2026, PolyPid's NDA acceptance decision and potential launch stretch into 2027, and Palvella's Phase 3 CVM trials and MLM NDA submission are both tracked for late 2026 and 2027, respectively. Lisata's legal recourse against Kuva Labs and the finalization of both the Niki BioSolutions and Vyne Therapeutics mergers remain the key structural items to watch across the group.

Which biopharma stocks moved the most today?

Lisata Therapeutics fell 36%, Palvella Therapeutics rose 16%, PolyPid fell 27%, and Vyne Therapeutics rose 11%, among the largest moves in the group.

Which companies reported clinical trial setbacks?

Celldex Therapeutics and Agios Pharmaceuticals both halted programs after trials failed to show sufficient differentiation from placebo, in prurigo nodularis and sickle cell disease, respectively.

Which companies were involved in mergers or corporate restructuring?

Niki BioSolutions completed its merger with DiamiR Biosciences, Vyne Therapeutics shareholders approved proposals to merge with Yarrow, Calidi Biotherapeutics disclosed a reverse stock split, and Lisata Therapeutics saw its planned acquisition by Kuva Labs collapse.